Clinical trials: Type Two Diabetes Mellitus
Diabetes Mellitus, Type 2
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D).
- Trial name
- NCT05478252
- Testing
- Semaglutide J, Semaglutide B
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Mechanisms of Glucose Lowering Effect of Colesevelam HCl
The mechanism by which colesevelam HCl lowers glucose is not known. Knowledge of the potential mechanism of action is important for defining the role of the drug among oral antidiabetic agents available for use in subjects with…
- Trial name
- NCT00596427
- Testing
- Colesevelam HCL
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Carine Beysen
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with…
- Trial name
- DUAL™ II (NCT01392573)
- Testing
- insulin degludec/liraglutide, insulin degludec
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 413 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)
This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin 50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of corresponding doses of sitagliptin and…
- Trial name
- NCT01093794
- Testing
- Co-administration of 50 mg sitagliptin and 500 mg metformin, sitagliptin/metformin 50 mg/500 mg tablet, Co-administration of 50 mg sitagliptin and 850 mg metformin
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Two Way Crossover Closed Loop MPC vs Control IQ
An artificial pancreas (AP) is a control system for automatic insulin delivery. The investigators have implemented a missed meal bolus detection algorithm for use within an AP control system.
- Trial name
- NCT05799781
- Testing
- MPC closed-loop system, t:slim X2 pump with Dexcom G6 CGM and Control IQ
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Oregon Health and Science University
Diabetic Kidney Disease
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
- Trial name
- NCT01752985
- Testing
- BMS-813160
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 319 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010), in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks of treatment.
- Trial name
- NCT01175473
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Liraglutide
- Where
- 7 sites in Germany
- Volunteers
- 148 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7%…
- Trial name
- NCT01215435
- Testing
- biphasic insulin aspart 30
- Where
- Iran
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart…
- Trial name
- BOOST® (NCT01680341)
- Testing
- insulin degludec/insulin aspart
- Where
- 45 sites in United States, Algeria and 3 more
- Volunteers
- 272 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-F1 (NCT00763451)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
This trial is conducted in Europe, Africa and the United States of America (USA). The aim of this trial is to compare the safety and efficacy of two different insulin treatments, the "basic" and the "advanced" treatment in type 2…
- Trial name
- NCT00537303
- Testing
- insulin detemir, insulin aspart
- Where
- 69 sites in United States, Denmark and 10 more
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
This trial is conducted in Europe, North America and the United States of America. The aim of this trial is to compare two different titration algorithms of insulin degludec/liraglutide.
- Trial name
- DUAL™ VI (NCT02298192)
- Testing
- insulin degludec/liraglutide
- Where
- 84 sites in United States, Austria and 7 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin detemir plus insulin aspart and NPH insulin plus human soluble insulin both in a basal bolus regimen with or without metformin in…
- Trial name
- NCT01486966
- Testing
- insulin detemir, insulin aspart, insulin NPH
- Where
- 6 sites in China
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 4 (NCT04880850)
- Testing
- Insulin icodec, Insulin glargine, Insulin aspart
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
The study will compare two combination therapies: 1) Combined Basal Insulin Glargine (once a day), Exenatide (twice a day), and Metformin Therapy; or 2) Combined Basal Insulin Glargine (once a day), Bolus Insulin Lispro (three…
- Trial name
- NCT00960661
- Testing
- exenatide, insulin lispro, Metformin
- Where
- 95 sites in Argentina, Belgium and 16 more
- Volunteers
- 1,036 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
The purpose of this study is twofold: 1. To evaluate the effect of LY2189265 on how the body absorbs a blood pressure lowering drug (lisinopril) in participants with high blood pressure who are currently taking lisinopril. 2.
- Trial name
- NCT01324388
- Testing
- LY2189265, Metoprolol, Lisinopril
- Where
- 3 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
- Trial name
- NCT00760578
- Testing
- Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
- Where
- 8 sites in United States
- Volunteers
- 86 people
- Sponsor
- Metabolic Solutions Development Company
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with…
- Trial name
- NCT00612040
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 33 sites in United States, Australia and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
- Trial name
- NCT00853151
- Testing
- LY2428757, TT223
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 131 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)
This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Levemir® (insulin detemir) administered once daily according to two titration algorithms after 20 weeks in subjects with type 2 diabetes…
- Trial name
- NCT01868542
- Testing
- insulin detemir
- Where
- 6 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S